A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC S. M. Lim,B. C. Cho,J-Y. Han,S-W. Kim, K. H. Lee, M. Nagasaka, T. R. Baisamut, A. Jo, E. Seah, C. Kim,S-H. I. OuAnnals of Oncology（2023）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
